Participated in Maxion Therapeutics' $72M oversubscribed Series A.
MAR 2025
Biotechnology company developing engineered protein therapeutics for previously untreatable or poorly treated diseases driven by ion channels and GPCRs
Biotechnology company developing engineered protein therapeutics for previously untreatable or poorly treated diseases driven by ion channels and GPCRs. Its patented KnotBody® platform fuses naturally occurring knottin miniproteins into antibody binding loops to create potent, selective, long-acting biologic medicines.